全身型幼年特发性关节炎治疗的新前沿
New frontiers in the treatment of systemic juvenile idiopathic arthritis.
作者信息
Canny Susan, Mellins Elizabeth
机构信息
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.
Department of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USA.
出版信息
F1000Res. 2017 Jun 22;6:971. doi: 10.12688/f1000research.11327.1. eCollection 2017.
Abstract
Systemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines, such interleukins 1 and 6, has changed the treatment paradigm for sJIA patients. In this review, we discuss the therapies currently used in the treatment of sJIA as well as novel targets and approaches under consideration, including mesenchymal stromal cell therapy and JAK inhibitors. We also discuss targeting cytokines that have been implicated in MAS, such as interferon gamma and interleukin 18.
摘要
全身型幼年特发性关节炎（sJIA）及其最严重的并发症巨噬细胞活化综合征（MAS），传统上一直使用类固醇和非甾体类抗炎药物进行治疗。然而，抑制特定细胞因子（如白细胞介素1和6）的生物药物的引入，改变了sJIA患者的治疗模式。在本综述中，我们讨论了目前用于治疗sJIA的疗法以及正在考虑的新靶点和方法，包括间充质基质细胞疗法和JAK抑制剂。我们还讨论了针对与MAS相关的细胞因子，如干扰素γ和白细胞介素18。
相似文献
1
New frontiers in the treatment of systemic juvenile idiopathic arthritis.全身型幼年特发性关节炎治疗的新前沿
F1000Res. 2017 Jun 22;6:971. doi: 10.12688/f1000research.11327.1. eCollection 2017.
2
Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ.全身型幼年特发性关节炎和噬血细胞性淋巴组织细胞增生症中的细胞因子：白细胞介素-18 和干扰素-γ之间的平衡倾斜。
Rheumatology (Oxford). 2015 Aug;54(8):1507-17. doi: 10.1093/rheumatology/keu524. Epub 2015 Mar 12.
3
The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.白细胞介素-1抑制在全身型幼年特发性关节炎中的作用：现状与未来展望。
Drug Des Devel Ther. 2018 Jun 8;12:1633-1643. doi: 10.2147/DDDT.S114532. eCollection 2018.
4
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.循环中干扰素-γ和干扰素-γ诱导的趋化因子水平升高的特征是并发全身幼年特发性关节炎的巨噬细胞活化综合征患者。
Ann Rheum Dis. 2017 Jan;76(1):166-172. doi: 10.1136/annrheumdis-2015-209020. Epub 2016 Jun 13.
5
Case report: Emapalumab for active disease control prior to hematopoietic stem cell transplantation in refractory systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome.病例报告：在难治性系统性幼年特发性关节炎合并巨噬细胞活化综合征的造血干细胞移植前，使用emapalumab控制疾病活动。
Front Pediatr. 2023 Feb 20;11:1123104. doi: 10.3389/fped.2023.1123104. eCollection 2023.
6
Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment.全身型幼年特发性关节炎与巨噬细胞活化综合征：发病机制与治疗的最新进展。
Curr Opin Rheumatol. 2018 Sep;30(5):514-520. doi: 10.1097/BOR.0000000000000526.
7
Treatment of systemic juvenile idiopathic arthritis.全身性幼年特发性关节炎的治疗。
Nat Rev Rheumatol. 2023 Dec;19(12):778-789. doi: 10.1038/s41584-023-01042-z. Epub 2023 Nov 3.
8
Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.卡那单抗用于治疗活动性全身型幼年特发性关节炎。
Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
9
Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.全身型幼年特发性关节炎患者的隐匿性巨噬细胞活化综合征
J Rheumatol. 2007 May;34(5):1133-8. Epub 2007 Mar 1.
10
Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).干扰干扰素：靶向全身型幼年特发性关节炎（SJIA）并发症中的 JAK-STAT 通路。
Rheumatology (Oxford). 2022 Mar 2;61(3):926-935. doi: 10.1093/rheumatology/keab673.
引用本文的文献
1
Identification of Key Biomarkers and Immune Infiltration in Systemic Juvenile Idiopathic Arthritis by Integrated Bioinformatic Analysis.通过综合生物信息学分析鉴定全身型幼年特发性关节炎的关键生物标志物和免疫浸润
Front Mol Biosci. 2021 Jul 14;8:681526. doi: 10.3389/fmolb.2021.681526. eCollection 2021.
2
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.托珠单抗皮下给药方案治疗儿童全身型或多关节型幼年特发性关节炎。
Rheumatology (Oxford). 2021 Oct 2;60(10):4568-4580. doi: 10.1093/rheumatology/keab047.
3
Transcriptome-Guided Drug Repositioning.转录组引导的药物重新定位
Pharmaceutics. 2019 Dec 12;11(12):677. doi: 10.3390/pharmaceutics11120677.
4
Investigations of cellular immunity in juvenile idiopathic arthritis.青少年特发性关节炎的细胞免疫研究。
Cent Eur J Immunol. 2019;44(1):92-96. doi: 10.5114/ceji.2019.83615. Epub 2019 Apr 15.
5
IL-6, IL-17 and Stat3 are required for auto-inflammatory syndrome development in mouse.白细胞介素-6、白细胞介素-17 和 Stat3 是小鼠自身炎症综合征发展所必需的。
Sci Rep. 2018 Oct 25;8(1):15783. doi: 10.1038/s41598-018-34173-5.
6
Impact of systemic juvenile idiopathic arthritis/Still's disease on adolescents as evidenced through social media posts.通过社交媒体帖子所证明的系统性幼年特发性关节炎/斯蒂尔病对青少年的影响。
Open Access Rheumatol. 2018 Jun 13;10:73-81. doi: 10.2147/OARRR.S165010. eCollection 2018.
7
Interleukin-1 in monocyte activation phenotypes in systemic juvenile idiopathic arthritis: Observations from a clinical trial of rilonacept, an interleukin-1 inhibitor.白细胞介素-1 在全身型幼年特发性关节炎单核细胞激活表型中的作用：利纳西普，一种白细胞介素-1 抑制剂临床试验的观察结果。
Clin Immunol. 2018 Sep;194:9-18. doi: 10.1016/j.clim.2018.06.005. Epub 2018 Jun 19.
8
The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.白细胞介素-1抑制在全身型幼年特发性关节炎中的作用：现状与未来展望。
Drug Des Devel Ther. 2018 Jun 8;12:1633-1643. doi: 10.2147/DDDT.S114532. eCollection 2018.
本文引用的文献
1
The emerging safety profile of JAK inhibitors in rheumatic disease.新型 JAK 抑制剂在风湿性疾病中的安全性概况。
Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2.
2
Haematopoietic stem cell transplantation for autoimmune diseases.造血干细胞移植治疗自身免疫性疾病。
Nat Rev Rheumatol. 2017 Apr;13(4):244-256. doi: 10.1038/nrrheum.2017.7. Epub 2017 Feb 23.
3
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.遗传结构将全身型幼年特发性关节炎与其他类型的幼年特发性关节炎区分开来：临床及治疗意义
Ann Rheum Dis. 2017 May;76(5):906-913. doi: 10.1136/annrheumdis-2016-210324. Epub 2016 Dec 7.
4
Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition.致命性 NLRC4 相关过度炎症经 IL-18 抑制治疗成功。
J Allergy Clin Immunol. 2017 May;139(5):1698-1701. doi: 10.1016/j.jaci.2016.10.022. Epub 2016 Nov 19.
5
Inflammatory Gene Expression Profile and Defective Interferon-γ and Granzyme K in Natural Killer Cells From Systemic Juvenile Idiopathic Arthritis Patients.全身性幼年特发性关节炎患者自然杀伤细胞中的炎症基因表达谱和缺陷型干扰素-γ及颗粒酶 K
Arthritis Rheumatol. 2017 Jan;69(1):213-224. doi: 10.1002/art.39933.
6
The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.儿童关节炎与风湿病研究联盟登记处的系统性幼年特发性关节炎队列研究：2010 - 2013年
J Rheumatol. 2016 Sep;43(9):1755-62. doi: 10.3899/jrheum.150997. Epub 2016 Jun 15.
7
Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.循环中干扰素-γ和干扰素-γ诱导的趋化因子水平升高的特征是并发全身幼年特发性关节炎的巨噬细胞活化综合征患者。
Ann Rheum Dis. 2017 Jan;76(1):166-172. doi: 10.1136/annrheumdis-2015-209020. Epub 2016 Jun 13.
8
Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.JAK1/2 阻断对小鼠噬血细胞性淋巴组织细胞增生症表现的治疗作用。
Blood. 2016 Jul 7;128(1):60-71. doi: 10.1182/blood-2016-02-700013. Epub 2016 May 24.
9
Macrophage activation syndrome in the era of biologic therapy.生物治疗时代的巨噬细胞活化综合征
Nat Rev Rheumatol. 2016 May;12(5):259-68. doi: 10.1038/nrrheum.2015.179. Epub 2016 Mar 24.
10
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.2016 年巨噬细胞活化综合征合并全身型幼年特发性关节炎分类标准：欧洲抗风湿病联盟/美国风湿病学会/儿科风湿病国际研究组织合作倡议
Ann Rheum Dis. 2016 Mar;75(3):481-9. doi: 10.1136/annrheumdis-2015-208982.
Zotero 插件